News & Updates
Filter by Specialty:
Semaglutide trims down weight in patients with severe obesity
Use of semaglutide 2.4 mg results in substantial weight reduction in patients with severe obesity who had previously undergone bariatric surgery (BS) but failed to achieve satisfactory weight loss, reports a recent study.
Semaglutide trims down weight in patients with severe obesity
12 Jan 2024
Linezolid flops against benzathine penicillin G for early syphilis
In the treatment of patients with early syphilis, a 5-day course of linezolid does not appear to perform as well as the standard of care benzathine penicillin G (BPG), as shown in a study.
Linezolid flops against benzathine penicillin G for early syphilis
12 Jan 2024
Mammo-50: Reduced mammogram frequency postsurgery may suffice for older women
Breast cancer survivors who are at least 50 years of age appear to do well with less frequent mammographic surveillance, with survival outcomes being no worse than with annual mammograms, according to data from the phase III Mammo-50 trial.
Mammo-50: Reduced mammogram frequency postsurgery may suffice for older women
11 Jan 2024
New models predict skeletal muscle mass reduction with calorie restriction
A recent study has shown that healthy men and women with overweight or obesity who undergo voluntary calorie restriction (CR), without a structure exercise program, attain decreases in skeletal muscle (SM) mass of approximately 2 to 2.5 kg and 1 to 1.5 kg per 10-kg weight loss, respectively.
New models predict skeletal muscle mass reduction with calorie restriction
11 Jan 2024
NIH study: Semaglutide associated with lower risk of suicidal ideation
Semaglutide is associated with a 49─73 percent lower risk of suicidal ideation vs other agents for treatment of obesity and type 2 diabetes mellitus (T2DM), a National Institutes of Health (NIH)─funded study has shown.